Results 1 to 10 of about 3,790 (190)
Pharmacological basis for antihypertensive effects of intravenous labetalol. [PDF]
Heart, 1977 Labetalol 1-5 mg/kg administered intravenously to normal subjects in the supine position produced an immediate mean fall in systolic (16%) and diastolic (25%) blood pressure with a concomitant increase in heart rate (12%). After graded exercise, intravenous labetalol inhibited increases in heart rate and blood pressure.
David Richards +4 more
openalex +4 more sources
Intravenous Labetalol for the Control of Hypertension Following Repair of Coarctation of the Aorta [PDF]
Clinical Cardiology, 1988 AbstractParadoxical hypertension is a relatively common complication of surgical repair of coarctation of the aorta. An early phase of systolic hypertension has been ascribed to elevated levels of norepinephrine. Activation of the renin‐angiotensin system from sympathetic stimulation has been implicated in a later phase of systolic and diastolic ...
Robert M. Bojar +2 more
openalex +3 more sources
Pakistan Armed Forces Medical Journal, 2018 Objective: To compare the outcome of oral Nifedipine & intravenous Labetalol in severe pregnancy induced hypertension in terms of time taken to achieve the target blood pressure. Study Design: Randomized controlled trial.
Riffat Sarwar +3 more
doaj +5 more sources
Intravenous labetalol in severe hypertension. [PDF]
British Journal of Clinical Pharmacology, 1982 1 Labetalol was administered by intravenous infusion or by the combination of intravenous bolus injection plus infusion to 15 patients with severe essential hypertension and to one with phaeochromocytoma. 2 With the infusion alone the reduction of arterial pressure was slow to develop and limited in degree, but with the combination of the bolus ...
Dal C. Palù +7 more
openalex +5 more sources
Hepatotoxicity Associated with Labetalol Use: A Case Report with Systematic Review and Disproportionality Analysis Using FAERS [PDF]
The Journal of Clinical Pharmacology, Volume 66, Issue 4, April 2026.Abstract Labetalol is widely prescribed as a first‐line antihypertensive in pregnancy; however, rare but potentially severe idiosyncratic hepatotoxicity has been reported, with a disproportionately strong reporting signal for liver injury relative to other β‐blockers.
Emma D. Hendriksen +2 more
wiley +2 more sources
Effects of early vs. late administration of labetalol on maternal cerebral perfusion and fetal growth in severe pre-eclampsia [PDF]
Frontiers in MedicineBackgroundSevere pre-eclampsia is a major contributor to maternal and perinatal morbidity and mortality worldwide. Antihypertensive therapy is essential, yet the impact of the timing of intravenous labetalol initiation on maternal cerebral hemodynamics ...
Jiahui Wang, Fangfang Yu
doaj +2 more sources
Efficacy and safety of Clevidipine for blood pressure control after carotid endarterectomy: a prospective cohort study [PDF]
Journal of Anesthesia, Analgesia and Critical CareBackground Strict postoperative blood pressure (BP) control within a narrow range is crucial after Carotid Endarterectomy (CEA) to minimize risks like stroke and hyperperfusion syndrome.
Vives M +5 more
doaj +2 more sources
Ain Shams Journal of Anesthesiology, 2019 Objective The aim of this study was to compare the effectiveness of two different protocols, labetalol with magnesium sulfate versus hydralazine with magnesium sulfate intravenous infusion with respect to their impact on maternal and fetal hemodynamics ...
Tamer Nabil Abdelrahman +3 more
doaj +2 more sources
Treatment of Hypertension in the Inpatient Setting: Use of Intravenous Labetalol and Hydralazine [PDF]
The Journal of Clinical Hypertension, 2009 J Clin Hypertens (Greenwich). 2010;12:29–33. ©2009 Wiley Periodicals, Inc.Acute blood pressure elevations are commonly treated in hospitalized patients. There are no guidelines for appropriate practice and no evidence that such treatment is useful.
Alan B. Weder, Steven R. Erickson
openalex +4 more sources
Safety of high-dose intravenous labetalol in hypertensive crisis
American Journal of Health-System Pharmacy, 2019 The study assesses the safety of high-dose intravenous (i.v.) labetalol in adults.This is a retrospective administrative record review of 28 hospitals in one health care system, from October 2010 through October 2015. Patients were included if they received 300 mg of i.v. labetalol within a 24-hour period.
Jason Hecht
exaly +3 more sources